Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas

Cancer Letters

Volumn 301, Issue 2, 2011, Pages 203-211

  Macher Goeppinger, Stephan ^a,b   Bermejo, Justo Lorenzo ^a   Wagener, Nina ^a   Hohenfellner, Markus ^a   Haferkamp, Axel ^c   Schirmacher, Peter ^a   Roth, Wilfried ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; CD95 (Fas APO1); Prognostic factors; Renal cell cancer

Indexed keywords

FAS ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

AGED; ANTIGENS, CD95; CARCINOMA, RENAL CELL; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78651467233     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.12.005     Document Type: Article

References (70)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin. 2009, 59(2009):225-249.
2. S.F. Altekruse, C.L. Kosary, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, J. Ruhl, N. Howlader, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, K. Cronin, H.S. Chen, E.J. Feuer, D.G. Stinchcomb, B.K. Edwards (Eds.), SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD (SEER data submission, posted to the SEER web site, 2010). November 2009. http://seer.cancer.gov/csr/1975_2007/.
3. Rosenberg S.A. Interleukin 2 for patients with renal cancer. Nat. Clin. Pract. Oncol. 2007, 4:497.
4. McDermott D.F. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009, 115:2298-2305.
5. Rini B.I. Metastatic renal cell carcinoma: many treatment options, one patient. J. Clin. Oncol. 2009, 27:3225-3234.
6. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
7. Begley J., Ribas A. Targeted therapies to improve tumor immunotherapy. Clin. Cancer Res. 2008, 14:4385-4391.
8. Seki N., Brooks A.D., Carter C.R.D., Back T.C., Parsoneault E.M., Smyth M.J., Wiltrout R.H., Sayers T.J. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 2002, 168:3484-3492.
9. Caldwell S.A., Ryan M.H., McDuffie E., Abrams S.I. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J. Immunol. 2003, 171:2402-2412.
10. Wagener N., Crnković-Mertens I., Vetter C., Macher-Göppinger S., Bedke J., Gröne E.F., Zentgraf H., Pritsch M., Hoppe-Seyler K., Buse S., Haferkamp A., Autschbach F., Hohenfellner M., Hoppe-Seyler F. Expression of inhibitor of apoptosis protein Livin in renal cell carcinoma and non-tumorous adult kidney. Brit. J. Cancer 2007, 97:1271-1276.
11. Bilim V., Yuuki K., Itoi T., Muto A., Kato T., Nagaoka A., Motoyama T., Tomita Y. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Brit. J. Cancer 2008, 98:941-949.
12. Zantl N., Weirich G., Zall H., Seiffert B.M., Fischer S.F., Kirschnek S., Hartmann C., Fritsch R.M., Gillissen B., Daniel P.T., Häcker G. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 2007, 26:7038-7048.
13. Zeng Y., Wu X.X., Fiscella M., Shimada O., Humphreys R., Albert V., Kakehi Y. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int. J. Oncol. 2006, 28:421-430.
14. Macher-Goeppinger S., Aulmann S., Tagscherer K.E., Wagener N., Haferkamp A., Penzel R., Brauckhoff A., Hohenfellner M., Sykora J., Walczak H., Teh B.T., Autschbach F., Herpel E., Schirmacher P., Roth W. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin. Cancer Res. 2009, 15:650-659.
15. Macher-Goeppinger S., Aulmann S., Wagener N., Funke B., Tagscherer K.E., Haferkamp A., Hohenfellner M., Kim S., Autschbach F., Schirmacher P., Roth W. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008, 10:1049-1056.
16. Nagata S., Golstein P. The Fas death factor. Science 1995, 267:1449-1456.
17. Peter M.E., Krammer P.H. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol. 1998, 10:545-551.
18. Roth W., Isenmann S., Nakamura M., Platten M., Wick W., Kleihues P., Bähr M., Ohgaki H., Ashkenazi A., Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 2001, 61:2759-2765.
19. Kojima Y., Tsurumi H., Goto N., Shimizu M., Kasahara S., Yamada T., Kanemura N., Hara T., Sawada M., Saio M., Yamada T., Takahashi T., Tomita E., Takami T., Moriwaki H. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur. J. Haematol. 2006, 76:465-472.
20. Minas V., Rolaki A., Kalantaridou S.N., Sidiropoulos J., Mitrou S., Petsas G., Jeschke U., Paraskevaidis E.A., Fountzilas G., Chrousos G.P., Pavlidis N., Makrigiannakis A. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Brit. J. Cancer 2007, 97:637-645.
21. Yamana K., Bilim V., Hara N., Kasahara T., Itoi T., Maruyama R., Nishiyama T., Takahashi K., Tomita Y. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Brit. J. Cancer 2005, 93:544-551.
22. Okazaki T., Sakamuro D. Induction of Fas (CD95/APO-1) ligand is essential for p53-dependent apoptosis in an in vitro renal carcinoma model system. J. Cancer Res. Clin. Oncol. 2007, 133:581-588.
23. Sejima T., Isoyama T., Miyagawa I. Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma. Int. J. Urol. 2003, 10:476-484.
24. D.A. Karnofsky, J.H. Burchenal. The clinical evaluation of chemotherapeutic agents in cancer. In: C.M. MacLeod (Ed.), Evaluation of Chemotherapeutic Agents, Columbia University Press, New York, 1949, p. 196.
25. Verbeke C.S., Wenthe U., Grobholz R., Zentgraf H. Fas ligand expression in Hodgkin lymphoma. Am. J. Surg. Pathol. 2001, 25:388-394.
26. von Reyher U., Sträter J., Kittstein W., Gschwendt M., Krammer P.H., Möller P. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 1998, 58:526-534.
27. Viard-Leveugle I., Veyrenc S., French L.E., Brambilla C., Brambilla E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J. Pathol. 2003, 201:268-277.
28. Ito Y., Monden M., Takeda T., Eguchi H., Umeshita K., Nagano H., Nakamori S., Dono K., Sakon M., Nakamura M., Tsujimoto M., Nakahara M., Nakao K., Yokosaki Y., Matsuura N. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Brit. J. Cancer 2000, 82:1211-1217.
29. Ramp U., Bretschneider U., Ebert T., Karagiannidis C., Willers R., Gabbert H.E., Gerharz C.D. Prognostic implications of CD95 receptor expression in clear cell renal carcinomas. Human Pathol. 2003, 34:174-179.
30. Kim Y.S., Kim K.H., Choi J.A., Lee J.H., Kim H.K., Won N.H., Kim I. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors. Arch. Pathol. Lab. Med. 2000, 124:687-693.
31. Sejima T., Miyagawa I. Significance of Fas expression alteration during tumor progression of renal cell carcinoma. Int. J. Urol. 2006, 13:257-264.
32. Salvi A., Marchina E., Benetti A., Grigolato P., De Petro G., Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int. J. Oncol. 2008, 33:271-276.
33. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.J., Walther M.M., Tsui L.C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L., Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S., Lerman M.I., Linehan W.M., Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 1997, 16:68-73.
34. Moumen A., Ieraci A., Patané S., Solé C., Comella J.X., Dono R., Maina F. Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner. Hepatology 2007, 45:1210-1217.
35. Schulze-Bergkamen H., Brenner D., Krueger A., Suess D., Fas S.C., Frey C.R., Dax A., Zink D., Büchler P., Müller M., Krammer P.H. Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 2004, 39:645-654.
36. Huh C., Factor V.M., Sánchez A., Uchida K., Conner E.A., Thorgeirsson S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. USA 2004, 101:4477-4482.
37. Suzuki H., Toyoda M., Horiguchi N., Kakizaki S., Ohyama T., Takizawa D., Ichikawa T., Sato K., Takagi H., Mori M. Hepatocyte growth factor protects against Fas-mediated liver apoptosis in transgenic mice. Liver Int. 2009, 29:1562-1568.
38. van Geelen C.M., Westra J.L., de Vries E.G., Boersma-van Ek W., Zwart N., Hollema H., Boezen H.M., Mulder N.H., Plukker J.T., de Jong S., Kleibeuker J.H., Koornstra J.J. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J. Clin. Oncol. 2006, 24:4998-5004.
39. McCarthy M.M., Sznol M., DiVito K.A., Camp R.L., Rimm D.L., Kluger H.M. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin. Cancer Res. 2005, 11:5188-5194.
40. Spierings D.C.J., de Vries E.G.E., Timens W., Groen H.J.M., Boezen H.M., de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin. Cancer Res. 2003, 9:3397-3405.
41. Garcia J.A., Cowey C.L., Godley P.A. Renal cell carcinoma. Curr. Opin. Oncol. 2009, 21:266-271.
42. Rini B.I., Atkins M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009, 10:992-1000.
43. Gerharz C.D., Ramp U., Déjosez M., Mahotka C., Czarnotta B., Bretschneider U., Lorenz I., Müller M., Krammer P.H., Gabbert H.E. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab. Invest. 1999, 79:1521-1534.
44. Ramp U., Dejosez M., Mahotka C., Czarnotta B., Kalinski T., Wenzel M., Lorenz I., Müller M., Krammer P., Gabbert H.E., Gerharz C.D. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma. Brit. J. Cancer 2000, 82:1851-1859.
45. Wu X.X., Mizutani Y., Kakehi Y., Yoshida O., Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res. 2000, 60:2912-2918.
46. Oya M., Ohtsubo M., Takayanagi A., Tachibana M., Shimizu N., Murai M. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001, 20:3888-3896.
47. Ramp U., Caliskan E., Mahotka C., Krieg A., Heikaus S., Gabbert H.E., Gerharz C.D. Apoptosis induction in renal cell carcinoma by TRAIL and gamma-radiation is impaired by deficient caspase-9 cleavage. Brit. J. Cancer 2003, 88:1800-1807.
48. Song J.H., Kandasamy K., Kraft A.S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem. 2008, 283:25003-25013.
49. Li H., Cai X., Fan X., Moquin B., Stoicov C., Houghton J. Fas Ag-FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G263-275.
50. Wajant H., Pfizenmaier K., Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev. 2003, 14:53-66.
51. Peter M.E., Legembre P., Barnhart B.C. Does CD95 have tumor promoting activities?. Biochim. Biophys. Acta 2005, 1755:25-36.
52. Peter M.E., Budd R.C., Desbarats J., Hedrick S.M., Hueber A., Newell M.K., Owen L.B., Pope R.M., Tschopp J., Wajant H., Wallach D., Wiltrout R.H., Zörnig M., Lynch D.H. The CD95 receptor: apoptosis revisited. Cell 2007, 129:447-450.
53. Sancho-Martinez I., Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 2009, 8:838-842.
54. Green D.R. Cancer: a wolf in wolf's clothing. Nature 2010, 465:433.
55. Desbarats J., Birge R.B., Mimouni-Rongy M., Weinstein D.E., Palerme J., Newell M.K. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 2003, 5:118-125.
56. Ametller E., Garcia-Recio S., Costamagna D., Mayordomo C., Fernandez-Nogueira P., Carbo N., Pastor-Arroyo E.M., Gascon P., Almendro V. Tumor promoting effects of CD95 signaling in chemoresistant cells. Mol. Cancer 2010, 9:161.
57. Lee J., Sayers T.J., Back T.C., Wigginton J.M., Wiltrout R.H. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 2003, 8:151-160.
58. Li H., Fan X., Stoicov C., Liu J.H., Zubair S., Tsai E., Ste Marie R., Wang T.C., Lyle S., Kurt-Jones E., Houghton J. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterology 2009, 137:934-944. 944.e1-4.
59. Kleber S., Sancho-Martinez I., Wiestler B., Beisel A., Gieffers C., Hill O., Thiemann M., Mueller W., Sykora J., Kuhn A., Schreglmann N., Letellier E., Zuliani C., Klussmann S., Teodorczyk M., Gröne H., Ganten T.M., Sültmann H., Tüttenberg J., von Deimling A., Regnier-Vigouroux A., Herold-Mende C., Martin-Villalba A. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008, 13:235-248.
60. Shinohara H., Yagita H., Ikawa Y., Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res. 2000, 60:1766-1772.
61. Kreuz S., Siegmund D., Rumpf J., Samel D., Leverkus M., Janssen O., Häcker G., Dittrich-Breiholz O., Kracht M., Scheurich P., Wajant H. NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J. Cell Biol. 2004, 166:369-380.
62. Chen L., Park S., Tumanov A.V., Hau A., Sawada K., Feig C., Turner J.R., Fu Y., Romero I.L., Lengyel E., Peter M.E. CD95 promotes tumour growth. Nature 2010, 465:492-496.
63. Jarad G., Wang B., Khan S., DeVore J., Miao H., Wu K., Nishimura S.L., Wible B.A., Konieczkowski M., Sedor J.R., Schelling J.R. Fas activation induces renal tubular epithelial cell beta 8 integrin expression and function in the absence of apoptosis. J. Biol. Chem. 2002, 277:47826-47833.
64. Barnhart B.C., Legembre P., Pietras E., Bubici C., Franzoso G., Peter M.E. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J. 2004, 23:3175-3185.
65. Legembre P., Barnhart B.C., Peter M.E. The relevance of NF-kappaB for CD95 signaling in tumor cells. Cell Cycle 2004, 3:1235-1239.
66. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 1999, 5:412-417.
67. Sourbier C., Lindner V., Lang H., Agouni A., Schordan E., Danilin S., Rothhut S., Jacqmin D., Helwig J., Massfelder T. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. Cancer Res. 2006, 66:5130-5142.
68. Sourbier C., Danilin S., Lindner V., Steger J., Rothhut S., Meyer N., Jacqmin D., Helwig J., Lang H., Massfelder T. Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res. 2007, 67:11668-11676.
69. Tergaonkar H.ShenV. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14:348-363.
70. Papenfuss K., Cordier S.M., Walczak H. Death receptors as targets for anti-cancer therapy. J. Cell. Mol. Med. 2008, 12:2566-2585.